Partner with us
We collaborate with biotech partners to jointly progress new treatments towards the clinic and build each other’s rare disease pipelines
Licensing and co-development
The success of our approach lies in its efficiency. An extension of that efficiency is our pursuit of licensing and co-development programmes with industry partners whose needs and expertise complement our own.
- Out-licensing pre- and post-clinical programmes
- In-licensing promising clinic-ready programmes
- Co-development with companies interested in rare disease indications